David S.

As of Friday, April 30, Ohana Biosciences will cease operations. We are thankful to the Ohana team, patients, clinicians, and many other people who helped us on our journey to help people facing reproductive health challenges. For future inquiries, please reach out to info@ohanabio.com.

MedAnswers builds highly engaged disease communities through easy-to-use engagement platforms for both patients and professionals. We match consumers with a network of trusted experts who can answer their personal questions, provide access to life-affirming clinical trials and use machine learning to match users to research, products and solutions specific to their health needs. Life-sciences companies can receive high-value market data products including hard-to-get behavioral data, natural history data and real world evidence. Researchers can recruit more patients for their clinical trials in half the amount of time with 83% opt-in rates to participate. Our flagship platform, FertilityAnswers, amassed a 250M+ data set with 65,000 users including behavioral insights, lifestyle, buying and non-buying decision making. These insights span the entire patient journey from struggle to treatment, identifying gaps in access, racial disparities, knowledge disparities, and so much more. With thousands of insights available, the company launched medinsights.medanswers.com for scalable dashboard access for our partners. The company is rapidly expanding into neurology, oncology and immunology through both out-licensing and in-house brand development.

Celmatix Therapeutics is a preclinical-stage women’s health biotech focused on advancing groundbreaking therapeutics for women’s health. With its growing pipeline of innovative drug programs including an AMHR2 agonist program focused on ovarian aging, an oral FSH for infertility, and a JNK inhibitor program for endometriosis, Celmatix Therapeutics is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in women’s health. For more information, visit the company’s website at www.celmatix.com.

𝗧𝗛𝗘 𝗡𝗘𝗫𝗧 𝗚𝗘𝗡𝗘𝗥𝗔𝗧𝗜𝗢𝗡 𝗢𝗙 𝗘𝗚𝗚 𝗔𝗡𝗗 𝗘𝗠𝗕𝗥𝗬𝗢 𝗦𝗧𝗢𝗥𝗔𝗚𝗘 TMRW Life Sciences is a fertility technology company that provides safety and transparency to modernize and transform egg and embryo storage.   The current system is manual, outdated, and stressful for embryologists and clinicians. Automatization and state-of-the-art technology identify, track and remotely monitor frozen eggs and embryos. TMRW is a scalable solution for overcrowded clinics that have unintentionally become storage facilities since the rise in people seeking fertility treatments. Named Fast Company's #1 Most Innovative Biotech Company in 2022, TMRW is in leading clinics across the US and will soon be available in the UK and Europe.

Hamilton Thorne, Inc. (HTI) manufactures and markets precision laser systems, imaging systems, consumables, software, and services that reduce cost, increase productivity, improve results, and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. HTI’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

As of Friday, April 30, Ohana Biosciences will cease operations. We are thankful to the Ohana team, patients, clinicians, and many other people who helped us on our journey to help people facing reproductive health challenges. For future inquiries, please reach out to info@ohanabio.com.

MedAnswers builds highly engaged disease communities through easy-to-use engagement platforms for both patients and professionals. We match consumers with a network of trusted experts who can answer their personal questions, provide access to life-affirming clinical trials and use machine learning to match users to research, products and solutions specific to their health needs. Life-sciences companies can receive high-value market data products including hard-to-get behavioral data, natural history data and real world evidence. Researchers can recruit more patients for their clinical trials in half the amount of time with 83% opt-in rates to participate. Our flagship platform, FertilityAnswers, amassed a 250M+ data set with 65,000 users including behavioral insights, lifestyle, buying and non-buying decision making. These insights span the entire patient journey from struggle to treatment, identifying gaps in access, racial disparities, knowledge disparities, and so much more. With thousands of insights available, the company launched medinsights.medanswers.com for scalable dashboard access for our partners. The company is rapidly expanding into neurology, oncology and immunology through both out-licensing and in-house brand development.

Celmatix Therapeutics is a preclinical-stage women’s health biotech focused on advancing groundbreaking therapeutics for women’s health. With its growing pipeline of innovative drug programs including an AMHR2 agonist program focused on ovarian aging, an oral FSH for infertility, and a JNK inhibitor program for endometriosis, Celmatix Therapeutics is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in women’s health. For more information, visit the company’s website at www.celmatix.com.

𝗧𝗛𝗘 𝗡𝗘𝗫𝗧 𝗚𝗘𝗡𝗘𝗥𝗔𝗧𝗜𝗢𝗡 𝗢𝗙 𝗘𝗚𝗚 𝗔𝗡𝗗 𝗘𝗠𝗕𝗥𝗬𝗢 𝗦𝗧𝗢𝗥𝗔𝗚𝗘 TMRW Life Sciences is a fertility technology company that provides safety and transparency to modernize and transform egg and embryo storage.   The current system is manual, outdated, and stressful for embryologists and clinicians. Automatization and state-of-the-art technology identify, track and remotely monitor frozen eggs and embryos. TMRW is a scalable solution for overcrowded clinics that have unintentionally become storage facilities since the rise in people seeking fertility treatments. Named Fast Company's #1 Most Innovative Biotech Company in 2022, TMRW is in leading clinics across the US and will soon be available in the UK and Europe.

RESOLVE: The National Infertility Association, established in 1974, is a non-profit organization with the only established, nationwide network mandated to promote reproductive health and to ensure equal access to all family building options for men and women experiencing infertility or other reproductive disorders. RESOLVE improves the lives of women and men living with infertility. One in eight U.S. couples of childbearing age is diagnosed with infertility. RESOLVE addresses this public health issue by providing community to these women and men, connecting them with others who can help, empowering them to find resolution and giving voice to their demands for access to all family building options. RESOLVE is a member of the National Coalition for Oversight of Assisted Reproductive Technologies (NCOART), the National Health Council and is a founding member of the International Federation of Infertility Patient Associations (IFIPA). RESOLVE will not discriminate against any person on the basis of race, creed, color, national origin, marital status, gender, sexual orientation, disability or any other classification protected by applicable state or federal law.